Director William J Link sold 22.9K shares (complete exit) for $1.9M at $81.26 avg; stock now $77.77
Director William J Link executed five separate sales on 2025-12-15 totaling 22,946 shares for $1,864,677.82, liquidating his entire position (from 22.9K shares to zero). The sales were executed across a narrow band ($80.71–$82.39), with a blended average of $81.26, close to the 52-week high of $82.23. At his prior TARS transaction (2025-09-08), a similar sell generated positive 90-day returns (+43.5%), suggesting the earlier sale preceded a period of price strength rather than decline. The company remains unprofitable (net income $-12.6M) despite strong revenue growth of +948.6% year-over-year, signaling a development-stage biotech with elevated risk. A complete insider liquidation of this magnitude warrants investor scrutiny of the director's forward confidence in the company's execution and near-term milestones.
Director Link sold 27.1K shares of TARS at $57.00; stock now $54.33. Holds 143.3K post-sale.
Link, a director at the unprofitable biopharmaceutical firm, sold 27,116 shares at $57.00 on 2025-09-08, reducing his stake by 15.9% to 143,332 shares. The stock has since declined to $54.33, placing the sale near the 52-week high of $58.85 and representing the upper end of recent momentum—the stock is up 32.7% over 90 days and 8.5% over 30 days. Link's prior open-market sales across all tickers showed a 90-day well-timed rate of 0.00%, indicating his historical sells have occurred before subsequent stock increases rather than declines. Against this backdrop of recent acceleration and the company's negative net income of $-20,340,000 in the latest quarter, the timing and magnitude of this reduction warrant monitoring, though a material stake of 143.3K shares remains.
